Flags with the logo of Novo Nordisk, maker of Ozempic and Wegovy, in an undated photograph. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images
Danish drugmaker Novo Nordisk began selling its once-daily Wegovy weight-loss pill in the United States on Jan. 5 after the product received U.S. regulatory approval last month, offering a needle-free option in the booming obesity-drug market and amid intensifying competition with rival Eli Lilly.
The pill, approved last month by the U.S. Food and Drug Administration, will initially be sold in 1.5-milligram and 4-milligram doses priced at $149 per month for self-paying patients, Novo said in a statement. Commercially insured patients could pay about $25 per month under savings programs.
